论文部分内容阅读
目的观察依达拉奉对急性脑梗死患者内皮素1(ET1)及血清基质金属蛋白酶9(MMP-9)的影响。方法神经内科住院患者80例,随机分为对照组40例和治疗组40例,对照组治疗采用血栓通静脉注射,辛伐他汀、阿斯匹林片口服;治疗组在对照组用药基础上加用依达拉奉注射液30 mg静脉滴注,2次/d;2组疗程均为14 d,分别在治疗前、治疗第14 d及28 d后对其欧州卒中评分量表(ESS)、ET1、MMP-9水平进行评估。结果治疗前2组患者血清MMP-9及ET1水平差异无统计学意义(P>0.05);治疗后第14、28 d两组比较差异MMP-9及ET1水平均有统计学意义(P<0.05)。两组治疗前ESS评分比较差异无统计学意义(P>0.05);治疗后第14、28 d两组相应时间的比较差异均有统计学意义(均P<0.05);ET1、MMP-9下降水平及ESS评分随时间推移改善更加明显。结论依达拉奉注射液可以降低急性脑梗死患者血清MMP-9、ET1水平并有效改善急性脑梗死患者神经功能。
Objective To observe the effect of edaravone on endothelin 1 (ET1) and serum matrix metalloproteinase 9 (MMP-9) in patients with acute cerebral infarction. Methods 80 cases of neurology inpatients were randomly divided into control group 40 cases and treatment group 40 cases, the control group treated by thrombosis with intravenous injection, simvastatin, aspirin tablets; the treatment group in the control group based on the drug plus The patients were treated with edaravone 30 mg intravenously twice a day for 2 days. The two courses of treatment were 14 days. The ESR, ESS, ET1, MMP-9 levels were assessed. Results There was no significant difference in the serum levels of MMP-9 and ET1 between the two groups before treatment (P> 0.05). The levels of MMP-9 and ET1 were significantly different between the two groups on the 14th and 28th days after treatment (P <0.05 ). There was no significant difference in ESS score between the two groups before treatment (P> 0.05). There was significant difference in the corresponding time between the two groups on the 14th and 28th day after treatment (both P <0.05) Levels and ESS scores improved more significantly over time. Conclusion Edaravone can reduce the levels of serum MMP-9 and ET1 in patients with acute cerebral infarction and effectively improve the neurological function in patients with acute cerebral infarction.